Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review
Skin Appendage Disorders · 2023 · 9 (6) · 423-437
DOI: 10.1159/000531890 ↗Kurz gefasst
Fachartikel in der Zeitschrift Skin Appendage Disorders, online erschienen am 27.09.2023. Verfasst von Aditya K Gupta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Mediprobe Research Inc., London, ON, Canada. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Low-dose oral minoxidil (LDOM) has demonstrated a promising safety and efficacy profile in the treatment of various hair disorders, including male androgenetic alopecia (AGA) and female-pattern hair loss (FPHL); however, it lacks FDA approval. The usual LDOM starting dose for male AGA is 1–5 mg/day, depending on physician preference and the patient’s condition. For FPHL, it is 0.5–1 mg/day. The maximum dose is generally 5 mg/day. If patients respond well without major side effects, the dose may be gradually increased since the LDOM’s efficacy appears to be dose-dependent. Patients may use LDOM long term if the treatment outcome is satisfactory. The common side effects of LDOM are hypertrichosis and cardiovascular symptoms. Females are more prone to hypertrichosis than males. The side effects of LDOM can be categorized as (a) dose-dependent type A side effects (hypertrichosis and cardiovascular symptoms) and (b) idiosyncratic type B side effects (pericardial effusion). Minoxidil acts via multiple pathways. Although minoxidil has a relatively short half-life of around 4 h, its hypotensive effect may last approximately 72 h. Effective treatments for alopecia are limited. Therefore, LDOM could be an important addition to the available therapies for managing some hair disorders, including AGA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mediprobe Research Inc., London, ON, Canada.
- Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
- School of Pharmacy, BRAC University, Dhaka, Bangladesh.
- Department of Dermatology, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Zitieren
APA
Gupta, A. K., Talukder, M., Shemer, A., Piraccini, B. M., & Tosti, A. (2023). Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders, 9(6), 423-437. https://doi.org/10.1159/000531890
Vancouver
Gupta AK, Talukder M, Shemer A, Piraccini BM, Tosti A. Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders. 2023;9(6):423-437. doi:10.1159/000531890
BibTeX
@article{Gupta2023,
author = {Gupta, Aditya K and Talukder, Mesbah and Shemer, Avner and Piraccini, Bianca Maria and Tosti, Antonella},
title = {Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review},
journal = {Skin Appendage Disorders},
year = {2023},
volume = {9},
number = {6},
pages = {423--437},
doi = {10.1159/000531890}
}
EUVIMED